SCHEMBL7437398

SCHEMBL7437398

O=C(c1ccccc1)c1cc(O)c(O)cc1C(=O)c1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.64
MEN1 O00255 1/20 0.64
USP2 O75604 1/20 0.64
KMT2A Q03164 1/20 0.64
KEAP1 Q14145 1/20 0.64
NFE2L2 Q16236 1/20 0.64
MAPT P10636 3/20 0.59
KDM4E B2RXH2 2/20 0.59
LMNA P02545 2/20 0.59
HPGD P15428 2/20 0.59
CYP3A4 P08684 1/20 0.59
RECQL P46063 1/20 0.59
HSD17B10 Q99714 1/20 0.59
ALDH1A1 P00352 2/20 0.59
AKR1C3 P42330 1/20 0.58
ATM Q13315 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
CYP1A2 P05177 1/20 0.55
PGR P06401 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL170272 0.91 LMNA (0.66) GAAMEN1USP2KMT2AKEAP1
SCHEMBL30063117 0.91 LMNA (0.66) GAAMEN1USP2KMT2AKEAP1
SCHEMBL7046942 0.91 KMT2A (0.70) GAAMEN1USP2KMT2AKEAP1
SCHEMBL10959160 0.86 MEN1 (0.55) GAAMEN1USP2KMT2AKEAP1
SCHEMBL11012667 0.86 GAA (0.55) GAAMEN1USP2KMT2AKEAP1
SCHEMBL10964767 0.86 GAA (0.55) GAAMEN1USP2KMT2AKEAP1
SCHEMBL295850 0.84 KMT2A (0.68) GAAMEN1USP2KMT2AKEAP1
SCHEMBL245255 0.83 BCL2 (0.62) GAAMEN1USP2KMT2AKEAP1
SCHEMBL11102516 0.82 HPGD (0.53) GAAMEN1USP2KMT2AKEAP1
SCHEMBL9644368 0.82 AKR1C3 (0.59) GAAMEN1USP2KMT2AKEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020037931-A1 Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them PORTELA & C.A., S.A. (PT) 2002-03-28 US disclosed
EP-1167341-A1 Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them Portela & Ca., S.A. (PT) 2002-01-02 EP disclosed
WO-2001098250-A1 SUBSTITUTED NITRATED CATECHOLS, THEIR USE IN THE TREATMENT OF SOME CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM PORTELA & CA SA (PT) 2001-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037931-A1 Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them SLC6A2, COMT, SLC6A3 GAA 1183/4885MEN1 1966/4885USP2 2254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.